Participant may receive pembrolizumab up to 2 times before participant's cystectomy. Participant will no longer be able to take the study drug if intolerable side effects occur, if participant is unable to follow study directions, or if participant's doctor decides it is in participant's best interest to stop treatment with pembrolizumab and proceed to surgery right away.